Subdural effusions, often assoicated with sequelae, were evenly distributed between the two therapeutic groups, and the excess rate of neurological residua in the triple therapy group could not be attributed to this complication. A preliminary analysis of serial cerebrospinal fluid examinations failed to show any significant differences in the rates of return to normal in the two groups.

The mean hospital stay for both treatment groups was 19 days, with median stays of 16 and 17 days for those in the ampicillin and triple drugs groups, respectively. The prolonged hospital stays of all patients reflect the adherence to a rather stringent set of clinical criteria for the discontinuation of treatment (15).

In contrast to our earlier study (15), the complications of drug therapy were not significantly different in the two treatment groups. The rather high frequencies of rash and phlebitis in each treatment group are probably secondary to the large amounts of ampicillin given intravenously.

Times of death. Analysis of the deaths occurring in each group, by time after treatment was begun, revealed a different distribution in the single-drug group (Table 2). The thirdy of the deaths (Active (Active) in the ampicillin group and the deaths (Active (Active)) in the ampicillin group and the deaths (Active (Active)) in the ampicilling group (Table 2).

(Table 3). Two-thirds of the deaths (4 of six) in the ampicillin group occurred in the first 48 hr, whereas only 30% (4 of 13) of the deaths in the triple therapy group occurred during the first 2 days. The proportion of early deaths to the total numbers of patients in each group was similar, i.e., 4 of 140 (2.9%) on ampicillin and 4 of 124 (3.3%) on the triple therapy.

TABLE 1.—FREQUENCY OF DEATH AND SEVERE NEUROLOGICAL RESIDUA IN PATIENTS WITH ACUTE BACTERIAL MENINGITIS BY TREATMENT GROUP 1

	Results of treatment								
Treatment regimen assigned	Recovered, no residua		Recovered with residua		Died		Combined fatal- ity and residua		- Total
	Num- ber	Per- cent	Num- ber	Per- cent	Num- ber	Per- cent	Num- ber	Per- cent	number of patients
Ampicillin	123 96 219	87. 9 77. 4 83. 0	11 15 26	7. 8 12. 1 9. 8	6 13 19	4. 3 10. 5 7. 2	17 28 45	12. 1 22. 6 17. 0	140 124 264

¹ Drug dosages, patients excluded, and type of residua are explained in text.

TABLE 2.—DISTRIBUTION OF COMPLICATIONS OF DISEASE AND RESPONSE TO THERAPY BY TREATMENT GROUP

		Treatment regimen				
			Ampicillin		Triple	
Problems observed		Cases	Percent	Cases	Percent	
Persistent fever (100 F[R]>7 days)		27	20. 0	23	21.6	
Subdural effusion. Prolonged hospital stay (≥19 days). Complications of therapy (rash, eosinophilia, phlebitis, etc.). Hematological.		47 38 0	4. 5 35. 0 27. 6 0	36 30 3	5. 4 32. 2 27. 0 2. 7	

TABLE 3.—TIME OF DEATH AFTER INITIATION OF THERAPY BY TREATMENT GROUPS IN 2 SEPARATE SERIES OF PATIENTS WITH BACTERIAL MENINGITIS

Source of data	Single drug				Combination of drugs				
	Death		All	Total -	Death		All	Total	
	≥48 hr.	>48 hr.	deaths		≥48 hr.	>48 hr.	deaths	cases	
Lepper and Dowling (11) Percent Present report Percent	9 69 4 66. 7	31 2 33. 3	13 100 6 100	43 140	27. 2 4 30. 8	72. 8 9 69. 2	11 100 13 100	14 124	